Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers.

Int J Mol Sci · 2019 · PMC6982188 · PMID 31878223

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

A reversible RAS inhibitor would be highly significant to the oncology field at large and extremely valuable for the treatment of patients harboring RAS mutations other than G12C.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.